Liu, J. F., Brady, M., Matulonis, U. A., Miller, A., Kohn, E. C., Swisher, E., … Bookman, M. A. (2023). LBA45 Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa). In Annals of Oncology (Vol. 34, pp. S1285–S1285). Elsevier BV. https://doi.org/10.1016/j.annonc.2023.10.039

Liu, J. F., M. Brady, U. A. Matulonis, A. Miller, E. C. Kohn, E. Swisher, W. Tew, et al. “LBA45 Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa).” In Annals of Oncology, 34:S1285–S1285. Elsevier BV, 2023. https://doi.org/10.1016/j.annonc.2023.10.039.

Liu JF, Brady M, Matulonis UA, Miller A, Kohn EC, Swisher E, et al. LBA45 Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa). In: Annals of Oncology. Elsevier BV; 2023. p. S1285–S1285.

Liu, J. F., et al. “LBA45 Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa).” Annals of Oncology, vol. 34, Elsevier BV, 2023, pp. S1285–S1285. Crossref, doi:10.1016/j.annonc.2023.10.039.

Liu JF, Brady M, Matulonis UA, Miller A, Kohn EC, Swisher E, Tew W, Cloven N, Muller C, Bender D, Moore R, Michelin D, Waggoner S, Geller M, Fujiwara K, D’Andre S, Carney M, Secord AA, Walker J, Bookman MA. LBA45 Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa). Annals of Oncology. Elsevier BV; 2023. p. S1285–S1285.